Dual Focus Soft Contact Lens Wear Cessation Study

Myopia Clinical Trial

Official title:

MiSight Lens Wear Cessation Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05779072
• Other study ID #: MIST-402
• Status: Completed
• Phase: N/A
• Start date: March 1, 2019
• Est. completion date: March 1, 2021

Study information

• Verified date: March 2023
• Source: Coopervision, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effect of ceasing treatment with dual focus soft contact lenses.

Description:

This is a bilateral, open label, dispensing study with subjects who have completed dual focus soft contact lens wear treatment for either 3 or 6 years and who are refit to Proclear 1-day lens for 1 year.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 83
• Est. completion date: March 1, 2021
• Est. primary completion date: March 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 14 Years to 19 Years

Eligibility

Inclusion Criteria:

• Successfully completed the MIST-401 Parts 1 and 2
• Visual acuity (VA) with CLs better than +0.25 log MAR (>6/12 or >20/40) in both eyes
• No ocular pathology or other contraindication to contact lens wear
• Where applicable (dependent on local requirements), have:

1. read the Informed Assent

2. been given an explanation of the Informed Assent,

3. indicated an understanding of the Informed Assent and

4. signed the Informed Assent Form. Or

5. read the Informed Consent,

6. been given an explanation of the Informed Consent,

7. indicated an understanding of the Informed Consent and

8. signed the Informed Consent Form.

• Where applicable (dependent on local requirements), have their parent or legal

guardian:

1. read the Informed Consent,

2. been given an explanation of the Informed Consent,

3. indicated an understanding of the Informed Consent and

4. signed the Informed Consent Form.

• Along with their parent or guardian (if applicable), be capable of comprehending the nature of the study, and be willing and able to adhere to the instructions set forth in this protocol.
• Along with their parent or guardian (if applicable), agree to maintain the visit schedule and be able to keep all appointments as specified in the study protocol for the duration of the study.
• Agree to wear the assigned contact lenses for a minimum of 10 hours per day, at least 6 days per week, for the duration of the study and to inform the study investigator if this schedule is interrupted. (Wearing time may be modified by the study staff for health reasons.)
• Be in good general health, based on his/her and parent's/guardian's (if applicable) knowledge.
• Have best-corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye.

Exclusion Criteria:

• Regular use of ocular medications (prescription or over-the-counter).
• Current use of systemic medications which, in the investigators opinion, may significantly affect contact lens wear, tear film production, pupil size, accommodation or refractive state.
• Pregnant or lactating or planning a pregnancy at the time of enrolment.
• Known ocular or systemic disease such as, but not limited to: anterior uveitis or iritis, episcleritis or scleritis, glaucoma, Sjogren's syndrome, lupus erythematosus, scleroderma, or diabetes.
• Any ocular, systemic or neuro-developmental conditions that in the investigators opinion, could influence refractive development.
• Keratoconus or an irregular cornea.
• Biomicroscope findings that would contraindicate contact lens wear including, but not

limited to:

1. Any active anterior segment ocular disease that would contraindicate contact lens wear.

2. clinically significant (Grade 3 or 4) abnormalities of the anterior segment, lids, conjunctiva, sclera or associated structures.

• The investigator for any reason considers that it is not in the best interest of the subject to participate in the study.

Related Conditions & MeSH terms

• Myopia

Intervention

Device:
• Single Vision Soft Contact Lens
Subjects refit to Single Vision Soft Contact Lens for 1 year

Locations

Country	Name	City	State
Canada	University of Waterloo School of Optometry	Waterloo	Ontario
Portugal	University of Minho Clinical & Experiment Optometry Research Lab	Braga
Singapore	National University of Singapore Faculty of Medicine	Singapore
United Kingdom	Aston University Ophthalmic Research Group	Birmingham

Sponsors (2)

Lead Sponsor	Collaborator
Coopervision, Inc.	Visioncare Research Ltd.

Countries where clinical trial is conducted

Canada,  Portugal,  Singapore,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Spherical Equivalent Refractive Error (SERE)	Change in spherical equivalent refractive error (SERE) relative to baseline (i.e., at end of dual focus soft contact lens wear treatment of either 3 or 6 years). Cycloplegic autorefraction was used to measure refractive error.	1 year
Primary	Change in Axial Length (AL)	Change in axial length (AL) relative to baseline (i.e., at end of dual focus soft contact lens wear treatment of either 3 or 6 years). Partial coherence interferometry was used to measure axial length.	1 year